| Original language | English |
|---|---|
| Pages (from-to) | 422-429 |
| Number of pages | 8 |
| Journal | Haemophilia |
| Volume | 23 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2017 |
Keywords
- recombinant blood clotting factor 8
- blood clotting factor 8, adolescent
- adult
- Article
- clinical outcome
- controlled study
- cost effectiveness analysis
- disease severity
- health status
- hemophilia A
- human
- Italy
- late prophylaxis
- on demand therapy
- patient compliance
- priority journal
- prophylaxis
- quality adjusted life year
- sensitivity analysis
- therapy
- cost benefit analysis
- economics
- Markov chain
- quality of life, Cost-Benefit Analysis
- Factor VIII
- Hemophilia A
- Humans
- Markov Chains
- Quality of Life
Cite this
Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. / Coppola, A.; D'Ausilio, A.; Aiello, A.; Amoresano, S.; Toumi, M.; Mathew, P.; Tagliaferri, A.; Group, the Potter Study; Feola, G.; Molinari, A.C.; Santoro, C.; Rivolta, G.F.; Cultrera, D.B.; Gagliano, F.; Zanon, E.; Mancuso, M.E.; Valdrè, L.; Mameli, L.; Banov, L.; Di Minno, G.; Quintavalle, G.; Mazzucconi, M.G.; Negri, N.; Santagostino, E.
In: Haemophilia, Vol. 23, No. 3, 2017, p. 422-429.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy
AU - Coppola, A.
AU - D'Ausilio, A.
AU - Aiello, A.
AU - Amoresano, S.
AU - Toumi, M.
AU - Mathew, P.
AU - Tagliaferri, A.
AU - Group, the Potter Study
AU - Feola, G.
AU - Molinari, A.C.
AU - Santoro, C.
AU - Rivolta, G.F.
AU - Cultrera, D.B.
AU - Gagliano, F.
AU - Zanon, E.
AU - Mancuso, M.E.
AU - Valdrè, L.
AU - Mameli, L.
AU - Banov, L.
AU - Di Minno, G.
AU - Quintavalle, G.
AU - Mazzucconi, M.G.
AU - Negri, N.
AU - Santagostino, E.
PY - 2017
Y1 - 2017
KW - recombinant blood clotting factor 8
KW - blood clotting factor 8, adolescent
KW - adult
KW - Article
KW - clinical outcome
KW - controlled study
KW - cost effectiveness analysis
KW - disease severity
KW - health status
KW - hemophilia A
KW - human
KW - Italy
KW - late prophylaxis
KW - on demand therapy
KW - patient compliance
KW - priority journal
KW - prophylaxis
KW - quality adjusted life year
KW - sensitivity analysis
KW - therapy
KW - cost benefit analysis
KW - economics
KW - Markov chain
KW - quality of life, Cost-Benefit Analysis
KW - Factor VIII
KW - Hemophilia A
KW - Humans
KW - Markov Chains
KW - Quality of Life
U2 - 10.1111/hae.13185
DO - 10.1111/hae.13185
M3 - Article
VL - 23
SP - 422
EP - 429
JO - Haemophilia
JF - Haemophilia
SN - 1351-8216
IS - 3
ER -